THOROFARE, N.J., July 9, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that the Company's Board of Directors, led by Raymond F. Akers Jr., Ph.D., Co-founder and Executive Chairman, will ring The NASDAQ Closing Bell this afternoon in celebration of Akers' January 23, 2014 listing on The NASDAQ Capital Market.
Commenting on the bell ringing ceremony, Dr. Akers said: "Our IPO on NASDAQ at the beginning of this year signified a huge milestone for the Company and we are honored to ring the NASDAQ closing bell to mark this occasion today."
"Our listing on NASDAQ gave us the financial backing required to commercialize important inventions in the medical diagnostic industry," continued Dr. Akers. "Inventions that help physicians diagnose medical conditions and diseases quickly; rapid diagnostic tests that are more efficient and less costly than traditional methods; tests which we believe are the future of medicine; and tests that can put that information in the palm of your hand.
"I would like to thank NASDAQ for providing one of the best capital market platforms in the world which has enabled us to accelerate our growth."
A live webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live
For photos and tweets from the ceremony follow us at: www.twitter.com/AkersBio
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.
ABOUT NASDAQ OMX GROUP
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
CONTACT: Raymond F. Akers, Jr. PhD Executive Chairman of the Board Akers Biosciences, Inc. Tel. +1 856 848 8698 Twitter. @AkersBio Brendan Hopkins RedChip Companies, Inc. (US Investor Relations) Tel. +1 407 644 4256 x134 Ben Simons / Alexandra Roper Vigo Communications (UK Investor Relations) Tel. +44 (0)20 7016 9570 email@example.com
Source:Akers Biosciences, Inc.